Return to search results.
Complete title: A Phase I, Multicenter, Open-Label Dose Escalation Study of LDK378, Administered Orally in Adult Patients with Tumors Characterized by Genetic Abnormalities in Anaplastic Lymphoma Kinase (ALK)
|Research Study Number||20110186|
|Principal Investigator||Laura Chow|
Research Study Description
Eligibility Criteria (must meet the following to participate in this study)
Genders Eligible for Study: Both
- Tumor must be confirmed to be ALK positive
Other eligibility criteria may apply.
Exclusions (conditions that would prevent participation in this study)
- Active pancreatitis
- Active or chronic liver disease
- Other protocol-defined inclusion/exclusion criteria may apply
Other exclusion criteria may apply.
Hematologic Malignancies; Lymphoma
Disclaimer: We update this information regularly. However, what you read today may not be completely up to date.